However, sequencing of BRCA1 and BRCA2 requires the analysis of a number of amplicons—too large to be added to a panel like ours—designed to cover relevant markers for the largest possible number of tumor types following the needs of our medical center. This evidence concerns the gene BRCA2 and neoplasm.